Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

211 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The proportion of postmenopausal breast cancer cases in the Netherlands attributable to lifestyle-related risk factors.
van Gemert WA, Lanting CI, Goldbohm RA, van den Brandt PA, Grooters HG, Kampman E, Kiemeney LALM, van Leeuwen FE, Monninkhof EM, de Vries E, Peeters PH, Elias SG. van Gemert WA, et al. Among authors: elias sg. Breast Cancer Res Treat. 2015 Jul;152(1):155-162. doi: 10.1007/s10549-015-3447-7. Epub 2015 Jun 5. Breast Cancer Res Treat. 2015. PMID: 26044369 Free PMC article.
Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.
Goey KKH, Elias SG, van Tinteren H, Laclé MM, Willems SM, Offerhaus GJA, de Leng WWJ, Strengman E, Ten Tije AJ, Creemers GM, van der Velden A, de Jongh FE, Erdkamp FLG, Tanis BC, Punt CJA, Koopman M. Goey KKH, et al. Among authors: elias sg. Ann Oncol. 2017 Sep 1;28(9):2128-2134. doi: 10.1093/annonc/mdx322. Ann Oncol. 2017. PMID: 28911067 Free article. Clinical Trial.
Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials.
Goey KKH, Elias SG, Hinke A, van Oijen MGH, Punt CJA, Hegewisch-Becker S, Arnold D, Koopman M. Goey KKH, et al. Among authors: elias sg. Br J Cancer. 2017 Dec 5;117(12):1768-1776. doi: 10.1038/bjc.2017.382. Epub 2017 Nov 9. Br J Cancer. 2017. PMID: 29123255 Free PMC article. Clinical Trial.
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.
Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, Oosting SF, Schröder CP, Hiltermann TJN, van der Wekken AJ, Groen HJM, Kwee TC, Elias SG, Gietema JA, Bohorquez SS, de Crespigny A, Williams SP, Mancao C, Brouwers AH, Fine BM, de Vries EGE. Bensch F, et al. Among authors: elias sg. Nat Med. 2018 Dec;24(12):1852-1858. doi: 10.1038/s41591-018-0255-8. Epub 2018 Nov 26. Nat Med. 2018. PMID: 30478423 Clinical Trial.
Choosing the right strategy based on individualized treatment effect predictions: combination versus sequential chemotherapy in patients with metastatic colorectal cancer.
Kwakman JJM, van Kruijsdijk RCM, Elias SG, Seymour MT, Meade AM, Visseren FLJ, Punt CJA, Koopman M. Kwakman JJM, et al. Among authors: elias sg. Acta Oncol. 2019 Mar;58(3):326-333. doi: 10.1080/0284186X.2018.1564840. Epub 2019 Jan 18. Acta Oncol. 2019. PMID: 30657353 Free article. Clinical Trial.
211 results